ACLY-IN-4 是一种 ATP-柠檬酸裂解酶 (ACLY) 抑制剂,IC50 为 0.022 μM,Kd 为 0.19 μM,可结合 ACLY 的变构结合位点,具有降血脂、抗脂肪变性、改善胰岛素敏感性、抗氧化应激、抗炎和抗纤维化作用,可缓解肝脂肪变性、全身胰岛素抵抗、氧化应激、肝脏炎症及纤维化,并可用于代谢功能障碍相关脂肪性肝炎的研究。
ACLY-IN-4
产品编号: MS-H70393 分子式: C15H10O6 分子量: 286.24
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

ACLY-IN-4 是一种 ATP-柠檬酸裂解酶 (ACLY) 抑制剂,IC50 为 0.022 μM,Kd 为 0.19 μM,可结合 ACLY 的变构结合位点,具有降血脂、抗脂肪变性、改善胰岛素敏感性、抗氧化应激、抗炎和抗纤维化作用,可缓解肝脂肪变性、全身胰岛素抵抗、氧化应激、肝脏炎症及纤维化,并可用于代谢功能障碍相关脂肪性肝炎的研究。

生物实验数据

生物活性 ACLY-IN-4 is an ATP-citrate lyase (ACLY) inhibitor with an IC50 of 0.022 μM and a Kd of 0.19 μM that binds to the allosteric binding site of ACLY, exhibits hypolipidemic, anti-steatotic, insulin-sensitizing, anti-oxidative stress, anti-inflammatory, and anti-fibrotic effects, alleviates hepatic steatosis, systemic insulin resistance, oxidative stress, hepatic inflammation, and fibrosis, and can be used for research on metabolic dysfunction-associated steatohepatitis.
体外研究
(In Vitro)

ACLY-IN-4 (Compound C1) (50 μM; 4 h) 可抑制 Oleic acid (MS-M89265) 诱导的 shNC HepG2 细胞脂质蓄积,但该效应在 shACLY HepG2 细胞中被减弱,提示其作用机制依赖于 ACLY。
ACLY-IN-4 (50 μM; 24 h) 可通过依赖 ACLY 的机制下调 Oleic acid 诱导的 shNC HepG2 细胞中脂肪生成相关基因 (FASN、ACC1、SREBP-1c) 的表达。

Real Time qPCR

Cell Line: oleic acid (OA)-induced shNC and shACLY HepG2 cells
Concentration: 50 μM
Incubation Time: 24 h (with 1 mM OA)
Result: Significantly downregulated mRNA expression of FASN, ACC1, and SREBP-1c in OA-induced shNC HepG2 cells.
Abolished the downregulatory effect on mRNA expression of FASN, ACC1, and SREBP-1c in OA-induced shACLY HepG2 cells.
体内研究
(In Vivo)

ACLY-IN-4 (Compound C1) (10-30 mg/kg;腹腔注射;每日 1 次;持续 8 周) 可显著改善高脂饮食 (HFD) 诱导的小鼠 MASH 模型中的肝脏脂肪变性、全身胰岛素抵抗、氧化应激、炎症及纤维化。

Animal Model: C57BL/6J (male, 8 weeks old, 18-20 g, HFD-induced MASH)
Dosage: 10 mg/kg; 30 mg/kg
Administration: i.p.; daily; 8 weeks
Result: Reduced average body weight to 46.0 g (10 mg/kg) and 32.9 g (vs 49.5 g in HFD control).
Significantly reduced serum triglyceride (TG), total cholesterol (T-CHO), alanine aminotransferase (ALT), aspartate aminotransferase (AST), low-density lipoprotein cholesterol (LDL-C), liver weight, hepatic TG, and hepatic T-CHO at 10 mg/kg.
Restored serum high-density lipoprotein cholesterol (HDL-C) levels at 10 mg/kg.
Significantly reduced hepatic lipid accumulation (confirmed by Oil Red O staining) at 10 mg/kg.
Suppressed hepatic mRNA expression of lipogenic markers (FASN, LXR, SREBP-1c, HMGCR, ACC1, CD36) and pro-inflammatory/fibrotic markers (CD68, TNF-α, NLRP3, ASC, α-SMA) at 10 mg/kg.
Restored mRNA expression of fatty acid oxidation markers (PPARα, CPT1, PPARγ, AMPKα1) at 10 mg/kg.
Reduced hepatic malondialdehyde (MDA) levels at 10 mg/kg.
Reduced liver protein levels of FASN, ACC1, NLRP3, ASC, α-SMA while increasing PPARα levels at 10 mg/kg.
Showed greater reductions in body weight, serum and hepatic lipid parameters, liver weight, and hepatic lipid accumulation than the 10 mg/kg dose at 30 mg/kg.
Produced similar significant effects on gene and protein expression of lipogenic, fatty acid oxidation, inflammatory, and fibrotic markers as the 10 mg/kg dose at 30 mg/kg.
Nearly restored hepatocellular morphology to match the standard diet control group (confirmed by H&E staining) at 30 mg/kg.

化学信息

分子量 286.24
分子式 C15H10O6

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础